[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"smoking-cessation\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:smoking-cessation":27},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,118,0,25,[9,44,71,101,126,164,192,214,240,265,284,301,321,348,373,398,428,448,468,489,511,537,557,585,614],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100642464","smoking-cessation-counseling-performance-among-medical-interns-100642464",false,"NCT07650721","Smoking Cessation Counseling Performance Among Medical Interns","Effect of Artificial Intelligence-Assisted Interactive Case-Based Training on Smoking Cessation Counseling Performance Among Medical Interns","Inclusion Criteria:\n\n* Medical interns enrolled in the internship training program at the Faculty of Medicine, Assiut University during the study period.\n* Able to attend the training session and complete all study assessments, including the pre-test and post-test evaluations.\n\nExclusion Criteria:\n\n* Previous formal structured training in smoking cessation counseling based on the 5A model.\n* Previous participation in a smoking cessation counseling educational program within the preceding 12 months.\n* Failure to complete the assigned educational intervention.\n* Failure to complete either the pre-test or post-test assessment.\n* Withdrawal of consent at any stage of the study.","ALL","18 Years",{"count":20,"type":21},140,"ESTIMATED","INTERVENTIONAL",[24],"NA","Smoking remains one of the leading preventable causes of morbidity and mortality worldwide and is strongly associated with chronic respiratory diseases, cardiovascular disease, cancer, and premature death. Physicians play a central role in tobacco control through the delivery of smoking cessation counseling, and even brief physician advice has been shown to significantly increase smoking quit rates. The evidence-based 5A's model (Ask, Advise, Assess, Assist, and Arrange) is widely recommended as the standard framework for smoking cessation counseling.",[27],"Smoking Cessation",[27,29,30],"Artificial Intelligence","Medical Interns","RECRUITING","2026-08-18",{"date":34,"type":35},"2026-08-19","ACTUAL",{"date":37,"type":35},"2026-06-30",{"date":39,"type":21},"2026-10-01",{"name":41,"class":42},"Assiut University","OTHER",1,{"id":45,"slug":46,"hasResults":12,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":52,"sex":17,"minAge":53,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":22,"phases":56,"briefSummary":57,"conditions":58,"keywords":61,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":43},"100568251","evaluation-of-low-and-high-nicotine-tobacco-free-nicotine-pouches-100568251","NCT06678789","Evaluation of Low and High Nicotine Tobacco Free Nicotine Pouches","Evaluation of Low and High Nicotine Tobacco Free Nicotine Pouches as a Harm Reducing Substitute for Combustible Cigarettes - (Pack2Pouch)","Pack2Pouch","Inclusion Criteria:\n\n* Age 21+\n* current cigarette smoking (25+ days per previous month, 5 or more cigarettes\u002Fday, for greater than 1yr, greater than 100 lifetime cigarettes)\n* have not used TNFPs more than 5 times during their lifetime\n* willing and able to attend 2 in-person visits in Charleston (to assess biomarkers)\n* have internet access\n\nExclusion Criteria:\n\n* Lack of proficiency in English.\n* Use of other combustible tobacco products (i.e., cigars, cigarillos, hookahs) and\u002For other non-combusted nicotine\u002Ftobacco products (i.e., e-cigarettes, smokeless tobacco) in the past 30 days.\n* Current use of smoking cessation medications (i.e., varenicline, bupropion, nicotine replacement therapy).\n* Use of marijuana within the past month, and unwillingness to abstain from marijuana during course of study.\n* Medical conditions contraindicated to NRT use (including pregnancy, breastfeeding, and nursing, past month myocardial infarction, current untreated cardiac arrhythmia, current severe angina, current uncontrolled severe vascular disease).",true,"21 Years",{"count":55,"type":21},50,[24],"Tobacco-free oral nicotine pouches (such as Zyn brand) are a less harmful alternative to cigarette smoking. Pouches, however, contain nicotine, and addictive substance that is not risk-free. The present study is evaluating how well nicotine pouches, at different nicotine levels, help people switch away from smoking cigarettes. People who smoke cigarettes will be asked to answer questions about their tobacco product use and provide breath samples and cheek swab samples at an in-person visit to MUSC Charleston. Participants will then be provided with a 28-day supply of nicotine pouches, and will be asked to switch from smoking to pouches over the course of 4 weeks. Finally, participants will complete a final visit at MUSC, and will answer more questions about their tobacco use 1-month later.",[59,60,27],"Cigarette Smoking","Nicotine Dependence",[62],"Smoking",{"date":64,"type":35},"2026-08-20",{"date":66,"type":35},"2025-02-14",{"date":68,"type":21},"2027-05-28",{"name":70,"class":42},"Medical University of South Carolina",{"id":72,"slug":73,"hasResults":12,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":4,"eligibilityCriteria":77,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":78,"targetDuration":4,"studyType":22,"phases":80,"briefSummary":83,"conditions":84,"keywords":85,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":43},"100630449","phase-2-a-study-of-vagal-nerve-stimulation-in-conjunction-with-nrt-for-smoking-cessation-100630449","NCT07487818","A Study Of Vagal Nerve Stimulation In Conjunction With NRT For Smoking Cessation","Using Vagal Nerve Stimulation In Conjunction With NRT For Smoking Cessation","Inclusion Criteria:\n\n* 18 years of age or older at the time of consent.\n* Currently smoking at least 10 cigarettes\u002Fday\n* Motivated to stop smoking (on a scale of 0 to 10, motivation must be 3 or above);\n* Ability to participate fully in all aspects of the study.\n* Have the ability to provide informed consent.\n* Have no contraindicating comorbid health conditions that would interfere with study participation, as determined by the clinical investigators.\n\nExclusion Criteria:\n\n* Patients with a current moderate\u002Fsevere depression as assessed by a score of ≥10 on the Patient Health Questionnaire-9 (PHQ-9).\n* Patients who are or have used an investigational drug within the past 30 days.\n* Patients who are currently using medication(s) known to interact with varenicline.\n* Patients who have clinically significant acute\u002Fchronic progressive or unstable neurologic, hepatic, renal, cardiovascular, psychological, respiratory, or metabolic disease.\n* Patients with a known allergy to nicotine patches or varenicline.\n* Patients with a personal history of acute pancreatitis, hypoglycemia, acute kidney injury or impairment of renal function, type 1 diabetes or diabetic ketoacidosis, and\u002For severe gastrointestinal disease such as gastroparesis.\n* Patients with an active implantable medical device, such as a pacemaker, hearing aid implant, or any implanted electronic device.\n* Patients diagnosed with narrowing of the arteries (carotid atherosclerosis)\n* Patients who have had surgery to cut the vagus nerve in the neck (cervical vagotomy)\n* Patients with clinically significant hypertension, hypotension, bradycardia, or tachycardia\n* Patients who have a metallic device such as a stent, bone plate, or bone screw implanted at or near your neck\n* Patients who are using another device at the same time (e.g., TENS Unit, muscle stimulator) or any portable electronic device (e.g., mobile phone).\n* Women who are pregnant or lactating, or who are of childbearing potential and are likely to become pregnant during the medication phase but are not willing to use a reliable form of contraception, will also be excluded.\n\n  1. Reliable forms of contraception include oral contraception, diaphragm or condom (with spermicide), injections, intrauterine devices, surgical sterilization, and abstinence. The study does not include vulnerable populations.\n  2. Specifically, the study does not include fetuses, neonates, pregnant women, children (\\\u003C18 years of age), prisoners, institutionalized individuals, or other vulnerable populations.\n\n  i. All female participants of childbearing potential must have a negative pregnancy test and must agree to use approved contraception during study participation.",{"count":79,"type":21},150,[81,82],"PHASE2","PHASE3","The purpose of this study is to provide preliminary evidence for the efficacy of 12 weeks of vagal nerve stimulation (VNS) and nicotine replacement therapy (NRT) for increasing smoking abstinence rates.",[27],[86,87,88,89,90,91,92],"nicotine dependence","smoking","vagal nerve stimulator","VNS","varenicline","nicotine replacement therapy","nicotine patches","2026-08-17",{"date":34,"type":35},{"date":96,"type":35},"2026-04-15",{"date":98,"type":21},"2027-05-31",{"name":100,"class":42},"Mayo Clinic",{"id":102,"slug":103,"hasResults":12,"nctId":104,"briefTitle":105,"officialTitle":106,"acronym":107,"eligibilityCriteria":108,"healthyVolunteers":52,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":109,"targetDuration":4,"studyType":22,"phases":111,"briefSummary":112,"conditions":113,"keywords":114,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":119,"startDateStruct":120,"completionDateStruct":122,"leadSponsor":124,"locationsCount":43},"100600603","phase-2-trial-of-varenicline-with-nicotine-lozenges-and-a-smartphone-medication-adherence-intervention-for-smoking-cessation-100600603","NCT07099638","Trial of Varenicline With Nicotine Lozenges and a Smartphone Medication Adherence Intervention for Smoking Cessation","Randomized Factorial Trial of Varenicline With Nicotine Lozenges and a Smartphone Medication Adherence Intervention to Promote Smoking Cessation","COMBOII","Inclusion Criteria:\n\n* Able to provide documentation of identity (to prevent fraudulent enrollment) and Oklahoma residence (due to limitations on prescribing to out-of-state residents)\n* Reports daily smoking ≥5 cigarettes per day\n* Provides a breath CO sample ≥6ppm to verify current smoking\n* Willing to schedule a smoking cessation attempt within the next 1-2 weeks\n* Willing to abstain from smoking cannabis or other combustible products during the study\n* Willing to use varenicline and nicotine lozenges\n* Willing to participate in the study for ≈6 months\n* Able to demonstrate \\>6th grade literacy which is necessary to read intervention materials and complete study assessments\n\nExclusion Criteria:\n\n* Does not own a smartphone that is compatible with the study app\n* Using an FDA-approved smoking cessation medication within the past 30 days\n* Using oral nicotine products (e.g., pouches, chewing tobacco, snus) more than once per week (5+ times) during the past 30 days\n* History of seizures (varenicline contraindication)\n* History of allergic reaction to varenicline\n* Pregnant, planning to become pregnant, or currently breastfeeding\n* Unwilling or unable to use varenicline or nicotine lozenges for other reasons (e.g., severe dry mouth, past history of severe medication side effects)\n* Other medical reasons at the discretion of the prescribing physician (e.g., uncontrolled hypertension, recent myocardial infarction)\n* Weekly or more frequent use of combustible cannabis during the past 30 days with a score ≥2 on the Cannabis Use Disorder Identification Test-Short Form",{"count":110,"type":21},496,[81],"No published studies to date have evaluated the combined impact of varenicline and oral nicotine replacement therapy (NRT) on smoking cessation in a randomized trial. Oral NRT, such as nicotine lozenges, can provide acute relief from cravings\u002Fwithdrawal, and offers individuals the flexibility to deliver nicotine quickly, in contrast with the continuous, passive, and slow-acting delivery of the nicotine patch. Nevertheless, in clinical trials of other combination pharmacotherapies, participants' adherence to of oral NRT has been suboptimal, making it difficult to determine whether there is an added benefit. Given the near-ubiquity of smartphone ownership (85% of U.S. adults), it is plausible that smartphone-based medication adherence interventions could have a positive influence on pharmacotherapy adherence and smoking cessation. This investigative team has demonstrated the feasibility and potential efficacy of using combination varenicline plus oral NRT treatment to promote smoking cessation in a pilot factorial randomized trial. Likewise, pilot findings showed that medication adherence and smoking cessation rates were higher among those who received smartphone-based medication reminders than those who did not. The proposed study will enroll 496 adults who smoke cigarettes daily. The study will employ a 2x2 factorial design in which participants will be randomized to one of four combinations of two treatment factors: 1) pharmacological treatment (varenicline + nicotine lozenges vs. varenicline alone) and 2) smartphone medication adherence intervention (smartphone-based smoking cessation app with vs. without adherence components). The primary study outcomes will be biochemically-confirmed 7-day point prevalence abstinence at 26 weeks after a scheduled quit date, and medication adherence over the 13-week treatment period. Smartphone-based daily diaries will be employed to assess daily smoking and medication adherence. Notably, the proposed study will employ entirely remote assessment and treatment delivery strategies. Exploratory analyses will evaluate the potential interaction between medication type and the smartphone adherence intervention, and compare the influences of pharmacological treatment type and the medication adherence intervention on weekly physical symptoms (e.g., withdrawal, medication side effects). The overarching goal of the proposed research is to improve smoking cessation treatment and decrease cancer risk.",[27],[27,115,116,117,118],"Varenicline","Nicotine Lozenges","Medication Adherence","Smartphone Intervention",{"date":34,"type":35},{"date":121,"type":35},"2026-07-21",{"date":123,"type":21},"2029-06-01",{"name":125,"class":42},"University of Oklahoma",{"id":127,"slug":128,"hasResults":12,"nctId":129,"briefTitle":130,"officialTitle":131,"acronym":4,"eligibilityCriteria":132,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":133,"enrollmentInfo":134,"targetDuration":4,"studyType":22,"phases":136,"briefSummary":137,"conditions":138,"keywords":139,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":153,"lastUpdatePostDateStruct":154,"startDateStruct":156,"completionDateStruct":158,"leadSponsor":160,"locationsCount":163},"100651844","phase-3-a-study-to-evaluate-the-efficacy-and-safety-of-axs-05-for-smoking-cessation-in-adults-100651844","NCT07766655","A Study to Evaluate the Efficacy and Safety of AXS-05 for Smoking Cessation in Adults","A Randomized, Double-Blind, Placebo and Active-Controlled Trial to Evaluate the Efficacy and Safety of AXS-05 for Smoking Cessation in Adults","Inclusion Criteria:\n\n* Male or female, aged 18 to 65 (inclusive)\n\nExclusion Criteria:\n\n* Unable to comply with study procedures.\n* Medically inappropriate for study participation in the opinion of the investigator.","65 Years",{"count":135,"type":21},705,[82],"This study is a Phase 3, multicenter, randomized, double-blind, placebo- and active-controlled, parallel-group trial to evaluate the efficacy and safety of AXS-05 compared to placebo and bupropion for smoking cessation in adults.",[27],[140,62,141,142,143,144,145,146,147,148,149,150,151,152],"Smoking cessation","Cigarettes","AXS-05","Auvelity","Axsome Therapeutics","Dopamine reuptake inhibitor","Norepinephrine reuptake inhibitor","Dextromethorphan","Bupropion","NMDA Receptor Antagonist","Glutamate Modulator","Sigma-1 Receptor Agonist","Nicotinic Acetylcholine Receptor Antagonist","2026-08-11",{"date":155,"type":35},"2026-08-14",{"date":157,"type":21},"2026-08",{"date":159,"type":21},"2027-12",{"name":161,"class":162},"Axsome Therapeutics, Inc.","INDUSTRY",9,{"id":165,"slug":166,"hasResults":12,"nctId":167,"briefTitle":168,"officialTitle":169,"acronym":170,"eligibilityCriteria":171,"healthyVolunteers":52,"sex":17,"minAge":172,"maxAge":173,"enrollmentInfo":174,"targetDuration":4,"studyType":22,"phases":176,"briefSummary":177,"conditions":178,"keywords":182,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":153,"lastUpdatePostDateStruct":184,"startDateStruct":186,"completionDateStruct":188,"leadSponsor":190,"locationsCount":43},"100601549","evaluating-the-impact-of-connect-in-a-multilingual-population-100601549","NCT07111936","Evaluating the Impact of CONNECT in a Multilingual Population","Evaluating the Impact of CONNECT, a Novel Smoking Cessation Intervention, in a Diverse, Multilingual Population","CONNECT-ML","Inclusion Criteria:\n\n* Age 50-80 years old.\n* Current smokers defined at smoking at least one cigarette in past 7 days AND eligible for lung cancer screening (LCS) based on smoking history (\\>=20 pack year history)\n* California (CA) residents\n* Able to understand and comply with study procedures for the entire length of the study.\n* Ability of individual or legal guardian\u002Frepresentative to understand a written informed consent document, and the willingness to sign it.\n\nExclusion Criteria:\n\n* Non-smokers.\n* Individuals with a diagnosis of lung cancer.\n* Individuals receiving hospice care.\n* Individuals whose providers do not think that they should participate (e.g., psychiatric illness or significant cognitive impairment that would impede the individuals ability to participate).\n* Hearing and\u002For vision disabilities that would prevent participants from adequately receiving treatment components such as video or telephone counseling.","50 Years","80 Years",{"count":175,"type":21},439,[24],"This study aims to broaden the reach of the lung cancer screening (LCS) CONNECT program (NCT04149249, NCT06213532), by developing a version of the program to be available to multilingual communities. The CONNECT program encourages individuals who are undergoing lung cancer screening to also quit smoking by providing a personalized program which includes a video doctor with personalized responses, text message and telephone call support and connection with a pharmacist to assist in obtaining nicotine replacement medication. This clinical trial will develop and ultimately test how well the CONNECT Multilingual (CONNECT ML) program works to improve smoking cessation among current adult smokers within the Spanish and Cantonese speaking communities.",[27,179,180,181],"Smoking Cessation Counseling Ability and Practice","Smoking Cessation Counselling","Lung Cancer Screening",[183],"Multilingual",{"date":185,"type":35},"2026-08-13",{"date":187,"type":35},"2025-08-07",{"date":189,"type":21},"2028-03-31",{"name":191,"class":42},"University of California, San Francisco",{"id":193,"slug":194,"hasResults":12,"nctId":195,"briefTitle":196,"officialTitle":197,"acronym":198,"eligibilityCriteria":199,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":200,"targetDuration":4,"studyType":22,"phases":202,"briefSummary":203,"conditions":204,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":153,"lastUpdatePostDateStruct":206,"startDateStruct":207,"completionDateStruct":209,"leadSponsor":211,"locationsCount":213},"100496608","ending-tobacco-use-through-interactive-tailored-messaging-for-cambodian-people-living-with-hivaids-100496608","NCT05746442","Ending Tobacco Use Through Interactive Tailored Messaging for Cambodian People Living With HIV\u002FAIDS","Ending Tobacco Use Through Interactive Tailored Messaging for Cambodian People Living With HIV\u002FAIDS (Project END-IT)","ProjectENDIT","Inclusion Criteria:\n\n* 1\\) being aged ≥18 years\n* 2\\) being HIV-positive\n* 3\\) self-reporting as a current combustible cigarette smoker (smoked ≥100 cigarettes in lifetime and currently smoke ≥1 cigarettes\u002Fday)\n* 4\\) willing to set a date for a quit attempt within 2 weeks of study enrollment\n* 5\\) being able to provide written informed consent to participate\n* 6\\) being able to read Khmer (score ≥4 points on the Rapid Estimate of Adult Literacy in Medicine-Short Form\n\nExclusion Criteria:\n\n* 1\\) history of a medical condition that precludes use of nicotine replacement therapy\n* 2\\) physician\u002Fclinician deemed ineligible to participate based on medical or psychiatric condition\n* 3\\) enrolled in another cessation program or use of other cessation medications.",{"count":201,"type":21},800,[24],"The goal of this research study is to test how well an automated text messaging smoking treatment program helps smokers with HIV quit smoking.",[27,205],"HIV",{"date":185,"type":35},{"date":208,"type":35},"2023-01-11",{"date":210,"type":21},"2027-09-30",{"name":212,"class":42},"H. Lee Moffitt Cancer Center and Research Institute",3,{"id":215,"slug":216,"hasResults":12,"nctId":217,"briefTitle":218,"officialTitle":219,"acronym":4,"eligibilityCriteria":220,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":221,"targetDuration":4,"studyType":22,"phases":223,"briefSummary":224,"conditions":225,"keywords":227,"overallStatus":232,"whyStopped":4,"lastUpdateSubmitDate":233,"lastUpdatePostDateStruct":234,"startDateStruct":235,"completionDateStruct":236,"leadSponsor":238,"locationsCount":43},"100651235","the-effect-of-motivational-interviewing-on-smoking-behavior-among-nursing-students-100651235","NCT07758998","The Effect of Motivational Interviewing on Smoking Behavior Among Nursing Students","The Effect of Motivational Interviewing on Changing Smoking Behavior Among Nursing Students","Inclusion Criteria:\n\n* Nursing students currently enrolled in the study setting.\n* Aged 18 years or older.\n* Current cigarette smokers.\n* No self-reported health condition that would prevent participation in the intervention.\n* Willing and able to provide informed consent and participate in the study.\n\nExclusion Criteria:\n\n* Inability to complete all planned stages of the study.\n* Withdrawal of consent or voluntary discontinuation from the study at any time.",{"count":222,"type":21},87,[24],"Smoking is one of the leading preventable public health problems worldwide, particularly among young adults who are at increased risk of nicotine dependence. Nursing students represent an important target population because, as future health professionals, they are expected to play a significant role in tobacco control and smoking cessation counseling. The Transtheoretical Model (TTM) is one of the most widely used theoretical frameworks for promoting health behavior change. The aim of this study will be to determine the effect of Transtheoretical Model-based motivational interviewing on changing smoking behavior among nursing students.\n\nThis study will be planned as a single-group, quasi-experimental pretest-posttest intervention. Nursing students who smoke cigarettes and voluntarily agree to participate will be included in the study. At baseline, participants will complete a Demographic Information Form, the Fagerström Test for Nicotine Dependence, the Stages of Change questionnaire, the Self-Efficacy\u002FTemptation Scale, the Processes of Change Scale, and the Decisional Balance Scale.\n\nParticipants will receive Transtheoretical Model-based educational sessions and motivational interviewing interventions focusing on the health effects of smoking, reasons for smoking, the benefits of smoking cessation, identification of social support resources, relapse prevention strategies, and successful smoking cessation experiences. The Stages of Change questionnaire will be administered before each motivational interviewing session, and all outcome measures will be reassessed during follow-up evaluations. The study is expected to provide evidence regarding the effectiveness of Transtheoretical Model-based motivational interviewing in reducing smoking behavior, decreasing nicotine dependence, promoting progression through the stages of change, improving self-efficacy, enhancing the use of behavioral change processes, and supporting smoking cessation among nursing students.",[226,27],"Tobacco Use",[228,229,230,27,226,231],"motivational interviewing","Transtheoretical Model","Nursing Students","Smoking Behavior","NOT_YET_RECRUITING","2026-08-10",{"date":153,"type":35},{"date":157,"type":21},{"date":237,"type":21},"2026-12",{"name":239,"class":42},"Meral Feratoğlu Research",{"id":241,"slug":242,"hasResults":12,"nctId":243,"briefTitle":244,"officialTitle":245,"acronym":246,"eligibilityCriteria":247,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":248,"targetDuration":4,"studyType":22,"phases":250,"briefSummary":251,"conditions":252,"keywords":253,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":258,"lastUpdatePostDateStruct":259,"startDateStruct":260,"completionDateStruct":262,"leadSponsor":264,"locationsCount":43},"100558846","family-based-financial-incentives-intervention-for-smoking-cessation-100558846","NCT06556433","Family-Based Financial Incentives Intervention for Smoking Cessation","Alaska Native Family-Based, Financial Incentives Intervention for Smoking Cessation: An RCT","Aniqsaaq-RCT","Index Participant Inclusion Criteria:\n\n* Alaska Native\u002FAmerican Indian (ANAI) person (based on self-reported race) and reside in Alaska.\n* Age ≥18 years.\n* Self-report smoking in the past 7 days, biochemically verified with saliva cotinine ≥ 30 ng\u002FmL (positive result based on at-home saliva swab test provided by study team).\n* Smoked ≥ 3 cigarettes per day over the past 3 months.\n* Considering or willing to make a quit attempt.\n* Have or will nominate one adult family member to enroll with them.\n* Own or have access to a mobile phone or tablet with Internet and text messaging capabilities, or will be loaned an iPad for the study duration\n* Willing to upload photos of self during completion of smoking status tests.\n* Willing to complete and sign an Internal Revenue Service (IRS) W-9 tax identification form if they wish to receive payments on the study.\n* Willing to provide written informed consent and participate in study-related tests and procedures.\n\nIndex Participant Exclusion Criteria:\n\n* Already enrolled in the study with another family member.\n* Participated in a prior study phase.\n\nFamily Member Participant Inclusion Criteria (regardless of smoking status or residence with the index participant):\n\n* Age ≥18 years.\n* Defined as family and nominated by the index participant, or have an ANAI family member who is ≥18 years and smokes that they would like to support in quitting.\n* Own or have access to a mobile phone or tablet with Internet and text messaging capabilities, or will be loaned an iPad for the study duration.\n* Willing to complete and sign an IRS W-9 tax identification form if they wish to receive payments on the study.\n* Willing to provide written informed consent and participate in study related tests and procedures.\n\nBoth men and women, those from non-ANAI racial\u002Fethnic groups, and those who live outside of Alaska in the United States will be eligible family member participants.\n\nFamily Member Participant Exclusion Criteria:\n\n* Already enrolled with another family member.\n* Participated in a prior study phase.\n\nAfter the randomized controlled trial, qualitative interviews will be conducted with index participants, family member participants, and Alaska Tribal Health System Stakeholders to inform program implementation. Healthcare providers, cessation specialists, Elder advisors, and Tribal Health System leaders and stakeholders will be invited by the Alaska Native Tribal Health Consortium team and separately consented and interviewed.",{"count":249,"type":21},1312,[24],"The current study will conduct an RCT to evaluate the effectiveness of a family-based incentive intervention with Alaska Native\u002FAmerican Indian families. The experimental arm will be compared to a control arm on biochemically-confirmed smoking abstinence at 6- and 12-months post-intervention.",[27],[254,255,256,27,257],"Alaska Native","Family","Financial Incentive","Contingency Management","2026-08-06",{"date":233,"type":35},{"date":261,"type":35},"2024-09-03",{"date":263,"type":21},"2028-04-30",{"name":100,"class":42},{"id":266,"slug":267,"hasResults":12,"nctId":268,"briefTitle":269,"officialTitle":269,"acronym":270,"eligibilityCriteria":271,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":272,"targetDuration":4,"studyType":22,"phases":274,"briefSummary":275,"conditions":276,"keywords":4,"overallStatus":232,"whyStopped":4,"lastUpdateSubmitDate":277,"lastUpdatePostDateStruct":278,"startDateStruct":279,"completionDateStruct":281,"leadSponsor":282,"locationsCount":43},"100637102","llm-intervention-for-tobacco-in-underserved-populations-lift-up-100637102","NCT07620301","LLM Intervention for Tobacco in Underserved Populations (LIFT-UP)","LIFT-UP","Inclusion Criteria:\n\n* 18+ years old\n* Use ≥3 cigarettes\u002Fday on average\n* Motivated to quit in the next 30 days\n* Have a computer or tablet with internet access for 1:1 interviews\n* Speak English or Spanish\n* Home address is in an area characterized by persistent poverty\n\nExclusion Criteria:\n\n* None",{"count":273,"type":21},22,[24],"This study will test a tailored, multilingual tobacco cessation chatbot called LIFT-UP (LLM Intervention for Tobacco in Underserved Populations), designed to better meet the needs of people living in persistent poverty census tracts.\n\nThis study will use 1:1 semi-structured interviews to explore social drivers of health impacting TC, as well as digital access and preferences among those living in PPCTs. This qualitative approach enables guided yet flexible exploration of key domains while capturing unanticipated insights relevant to refining the chatbot.",[27],"2026-08-05",{"date":258,"type":35},{"date":280,"type":21},"2026-08-01",{"date":98,"type":21},{"name":283,"class":42},"University of Utah",{"id":285,"slug":286,"hasResults":12,"nctId":287,"briefTitle":288,"officialTitle":288,"acronym":4,"eligibilityCriteria":289,"healthyVolunteers":52,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":290,"targetDuration":4,"studyType":22,"phases":292,"briefSummary":293,"conditions":294,"keywords":4,"overallStatus":232,"whyStopped":4,"lastUpdateSubmitDate":295,"lastUpdatePostDateStruct":296,"startDateStruct":297,"completionDateStruct":298,"leadSponsor":300,"locationsCount":43},"100650950","libre-del-cigarrillo-development-of-an-mhealth-smoking-cessation-app-to-extend-reach-of-a-validated-smoking-cessation-intervention-for-spanish-speaking-smokers-100650950","NCT07754448","Libre Del Cigarrillo: Development of an mHealth Smoking Cessation App to Extend Reach of a Validated Smoking Cessation Intervention for Spanish-speaking Smokers","Inclusion Criteria:\n\n* Self-identify as Hispanic\u002FLatinx.\n* 18+ Years of age.\n* Monolingual Spanish-speaking, or bilingual Spanish-English and prefer educational health materials in Spanish.\n* Have been smoking at least 5 cigarettes per week over the past year\n* Not currently enrolled in a face-to-face or virtual smoking cessation program.\n\nExclusion Criteria:\n\n* A household member enrolled in the study.\n* Prior participation in the LDC randomized controlled trial.\n* Prior use of the NCI SmokefreeTXT program.",{"count":291,"type":21},120,[24],"Pilot randomized controlled trial evaluating feasibility, acceptability, and trial-readiness of the new app compared with the existing print booklets and the NCI SmokefreeTXT en Español program.",[27],"2026-08-04",{"date":233,"type":35},{"date":157,"type":21},{"date":299,"type":21},"2028-02",{"name":212,"class":42},{"id":302,"slug":303,"hasResults":12,"nctId":304,"briefTitle":305,"officialTitle":305,"acronym":4,"eligibilityCriteria":306,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":307,"targetDuration":4,"studyType":22,"phases":309,"briefSummary":310,"conditions":311,"keywords":313,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":295,"lastUpdatePostDateStruct":314,"startDateStruct":315,"completionDateStruct":317,"leadSponsor":319,"locationsCount":43},"100560864","refer2quit-evaluating-a-proactive-tailored-population-health-approach-for-tobacco-treatment-for-household-smokers-through-a-pediatric-care-network-100560864","NCT06582693","Refer2Quit: Evaluating a Proactive, Tailored, Population Health Approach for Tobacco Treatment for Household Smokers Through a Pediatric Care Network","Adult Intervention Subject Inclusion Criteria\n\n* Males or females ages ≥18 years in age\n* Self-identify as a current combustible tobacco user\n* Have a valid cell phone number\n\nChild Intervention Subject Inclusion Criteria\n\n* Must be a CHOP patient\n\nAdult Intervention Subject Exclusion Criteria\n\n* \\\u003C18 years in age.\n* Indicates no combustible tobacco smoking\n\nChild Intervention Subject Exclusion Criteria\n\n* Not a CHOP patient\n\nAdult Control Subject Inclusion Criteria\n\n* Males or females ages ≥18 years in age\n* Self-identify as a current combustible tobacco user\n* Have a valid cell phone number\n\nChild Control Subject Inclusion Criteria\n\n* Must be a CHOP patient\n\nAdult Control Subject Exclusion Criteria\n\n* \\\u003C18 years in age.\n* Indicates no combustible tobacco smoking\n\nChild Control Subject Exclusion Criteria\n\n* Not a CHOP patient",{"count":308,"type":21},3200,[24],"The goal of this clinical trial is to compare the reach and effectiveness of the Refer2Quit intervention for increasing tobacco use treatment and quit rates among household members who smoke versus a treatment as usual group. This clinical trial also aims to study household member and pediatric patient characteristics that are associated with reach and effectiveness of Refer2Quit.",[62,27,312],"Second Hand Tobacco Smoke",[62,27,312],{"date":258,"type":35},{"date":316,"type":35},"2024-09-06",{"date":318,"type":21},"2027-03-01",{"name":320,"class":42},"Children's Hospital of Philadelphia",{"id":322,"slug":323,"hasResults":12,"nctId":324,"briefTitle":325,"officialTitle":326,"acronym":4,"eligibilityCriteria":327,"healthyVolunteers":12,"sex":17,"minAge":53,"maxAge":133,"enrollmentInfo":328,"targetDuration":4,"studyType":22,"phases":330,"briefSummary":331,"conditions":332,"keywords":334,"overallStatus":232,"whyStopped":4,"lastUpdateSubmitDate":340,"lastUpdatePostDateStruct":341,"startDateStruct":342,"completionDateStruct":344,"leadSponsor":346,"locationsCount":4},"100642885","phase-2-thcv-treatment-for-smokers-100642885","NCT07636356","THCV Treatment for Smokers","Development of Tetrahydrocannabivarin as a Treatment for Smokers","Inclusion Criteria:\n\n1. Be between the ages of 21 and 65;\n2. Smoke 10 or more combustible cigarettes per day;\n3. Have fewer than 3 months of smoking abstinence in the past year;\n4. Has self-reported ≥10 lifetime uses of cannabis products;\n5. Have self-reported recent (past 3-month) use of cannabis products;\n6. Agree to abstain from all other cannabinoid use during the study;\n7. Agree to abstain from all other medication use during the study, other than methods of birth control as listed in inclusion criteria for female participants;\n8. Agree to one of the following methods of birth control (if female), unless she or partner are surgically sterile: oral contraceptives, Contraceptive sponge, patch, double barrier, intrauterine contraceptive device, etonogestrel implant, medroxyprogesterone acetate contraceptive injection, hormonal vaginal contraceptive ring, complete abstinence from sexual intercourse.\n\nExclusion Criteria:\n\n1. Have current (last 12 months) DSM-5 diagnosis of substance use disorder for any psychoactive substances other than nicotine;\n2. Have a lifetime DSM-5 diagnosis of schizophrenia, bipolar disorder, or any other psychotic disorder;\n3. Have a score of 3 or greater on the Columbia Suicide Severity Rating Scale (C-SSRS) at screening or anytime during study participation;\n4. Have a positive urine screen for any substances, including cannabis\n5. Have a breathalyzer reading above 0.000 g\u002Fdl;\n6. Be pregnant, nursing, or planning to become pregnant while taking part in the study;\n7. Have a medical condition that may interfere with safe study participation;\n8. Have clinically significant abnormalities on the EKG;\n9. Have evidence of renal impairment, defined by an eGFR value of \\\u003C90 ml\u002Fmin;\n10. Have evidence of hepatic impairment, defined by a score of ≥5 points on the Child-Pugh assessment of liver function;\n11. Exceed Grade 2 laboratory or vital sign abnormalities, based on FDA Guidance Document \"Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials\";\n12. Have past month use of cannabis or cannabis products;\n13. Have past month use of electronic nicotine delivery system (ENDS);\n14. Have use of any medications (other than methods of birth control as listed in inclusion criteria for female participants) within 14 days or 5 half-lives (whichever is longer) prior to study drug administration, and throughout the study, including medication for smoking cessation, any prescription, OTC, dietary supplements, herbal products, or vitamins;\n15. Have any other circumstances that, in the opinion of the investigators, would not be a good fit for study participation.",{"count":329,"type":21},32,[81],"This study will randomize 32 non-treatment-seeking individuals who smoke cigarettes daily into a randomized, crossover, double-blind, placebo-controlled study testing the safety, tolerability, and initial efficacy of Δ9-tetrahydrocannabivarin (Δ9-THCV).",[333,27],"Tobacco Use Disorder",[335,336,337,338,339],"smoking cessation","tobacco use disorder","cigarette smoking","THCV","Tetrahydrocannabivarin","2026-08-03",{"date":295,"type":35},{"date":343,"type":21},"2026-10",{"date":345,"type":21},"2028-05-31",{"name":347,"class":42},"University of California, Los Angeles",{"id":349,"slug":350,"hasResults":12,"nctId":351,"briefTitle":352,"officialTitle":353,"acronym":4,"eligibilityCriteria":354,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":355,"targetDuration":4,"studyType":22,"phases":357,"briefSummary":358,"conditions":359,"keywords":361,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":365,"lastUpdatePostDateStruct":366,"startDateStruct":367,"completionDateStruct":369,"leadSponsor":371,"locationsCount":43},"100504325","personalized-tobacco-treatment-in-primary-care-motivate-100504325","NCT05846841","Personalized Tobacco Treatment in Primary Care (MOTIVATE)","A Multilevel Intervention to Personalize and Improve Tobacco Treatment in Primary Care (MOTIVATE)","Eligibility Criteria for Primary and Specialty Care Clinicians\n\n* Clinician from participating clinic\n* At least 18 years of age\n* Can speak and understand English\n\nEligibility Criteria for Primary Care and Specialty Patients\n\nInclusion:\n\n* Patient at participating clinic\n* Age 18 years or older, inclusive\n* Current smoking (cigarettes per day \\>=5)\n* Can speak and understand English\n* Willing to consider medication to help reduce craving or smoking such as nicotine patch, lozenge, or varenicline\n\nExclusion:\n\n* Active use of smoking cessation medication (within the past 30 days)\n* Receipt of smoking cessation medication or prescription for smoking cessation medication (within the past 30 days)\n* Having a contraindication for cNRT or varenicline (allergic reactions, current cardiac problems, pregnancy)",{"count":356,"type":21},850,[24],"This study examines the application of precision treatment intervention for smoking cessation from both the clinician perspective and patient perspective, and compares it to usual care on tobacco treatment in the primary care setting. The precision treatment intervention includes personalized tobacco treatment recommendations using the patient's clinical, genetic, and biomarker information. This approach may increase effectiveness and adherence for the patient, and increase the clinician's likelihood of prescribing.",[360,27,62],"Physician's Role",[362,363,364],"genetics","primary care physicians","tobacco treatment","2026-07-30",{"date":340,"type":35},{"date":368,"type":35},"2023-09-29",{"date":370,"type":21},"2028-09-30",{"name":372,"class":42},"Washington University School of Medicine",{"id":374,"slug":375,"hasResults":12,"nctId":376,"briefTitle":377,"officialTitle":378,"acronym":379,"eligibilityCriteria":380,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":381,"targetDuration":4,"studyType":22,"phases":383,"briefSummary":384,"conditions":385,"keywords":386,"overallStatus":232,"whyStopped":4,"lastUpdateSubmitDate":391,"lastUpdatePostDateStruct":392,"startDateStruct":393,"completionDateStruct":394,"leadSponsor":396,"locationsCount":397},"100594066","smoking-cessation-program-for-lao-people-with-hiv-100594066","NCT07014605","Smoking Cessation Program for Lao People With HIV","Implementing Sustainable Mobile Health Technology to Optimize Smoking Cessation Program for Lao People With HIV","I-STOP","Inclusion Criteria:\n\n1. aged ≥18 years\n2. reachable within 30 days of the target assessment date by different methods (up to 4 phone calls on different days and times, 3 text messages for each platform \\[e.g., SMS, Telegram, or WhatsApp\\], 3 emails if applicable, and via direct contact at a prescheduled clinic appointment if applicable)\n3. consenting to be contacted after 6 months of enrollment and able to provide written informed consent to participate.\n\nExclusion Criteria:\n\n* None.",{"count":382,"type":21},1200,[24],"Tobacco use remains the leading modifiable risk factor for preventing cancer globally, particularly among people with HIV (PWH). In Laos, 61-80% of male PWH and 3-10% of female PWH smoke cigarettes. PWH who smoke in Laos have no reliable smoking cessation support. Thus, implementing sustainable and evidence-based smoking cessation interventions for PWH in Laos is needed. The investigators developed a scalable and affordable mHealth-based automated treatment program (MAP) to support Lao and Cambodian smokers to quit smoking. MAP involves interactive, tailored, personalized content (text messages, photos, and videos) delivered via a smartphone app. Along with effective cessation treatments, it is imperative to implement procedures to identify patients who smoke and to connect them to treatment. Our team pioneered the Ask-Advise-Connect (AAC, asking patients about smoking at every visit, briefly advising those who smoke to quit, and connecting them to treatment) approach, which showed great impact in our previous US studies. The purpose of this study is to compare 2 smoking cessation implementation strategies in 8 antiretroviral therapy (ART) clinics in the 6 most populous regions in Laos, using a hybrid type-2 pragmatic effectiveness-implementation study and a parallel cluster randomized trial design. Specifically, the investigators will compare an AAC approach paired with our previously developed MAP (AA-MAP) to an AAC approach paired with less resource-intensive printed self-help material (AA-SH). The investigators will use the Practical, Robust Implementation and Sustainability Model (PRISM), which expands the RE-AIM (Reach, Effectiveness, Adoption, Implementation, and Maintenance) framework to include more contextual factors relevant to program implementation. Aim 1 is to evaluate the reach and effectiveness of AA-MAP versus AA-SH. Reach is the proportion of PWH who smoke and are willing to make a quit attempt that enroll in treatment. Effectiveness is the proportion of enrolled participants who achieve biochemically confirmed point prevalence abstinence 6 months after enrollment. The investigators will also estimate the real-world impact (impact = reach × effectiveness) of each intervention. Aim 2 is to determine other implementation outcomes of AA-MAP and AA-SH. Aim 3 is to assess the resource use and costs of implementing AA-MAP and AA-SH. The project has the potential to transform HIV care and to reduce tobacco-related cancers and other morbidities.",[27,205],[335,387,388,389,390],"cancer control","implementation science","low- and middle-income countries","mobile health","2026-07-28",{"date":365,"type":35},{"date":157,"type":21},{"date":395,"type":21},"2029-07-31",{"name":125,"class":42},2,{"id":399,"slug":400,"hasResults":12,"nctId":401,"briefTitle":402,"officialTitle":403,"acronym":404,"eligibilityCriteria":405,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":406,"targetDuration":4,"studyType":22,"phases":408,"briefSummary":409,"conditions":410,"keywords":412,"overallStatus":232,"whyStopped":4,"lastUpdateSubmitDate":420,"lastUpdatePostDateStruct":421,"startDateStruct":422,"completionDateStruct":424,"leadSponsor":426,"locationsCount":43},"100610643","telegram-messenger-support-for-smoking-cessation-after-heart-attack-100610643","NCT07230249","Telegram Messenger Support for Smoking Cessation After Heart Attack","Effect of a Behavioral Intervention Delivered Via Telegram Messenger on Smoking Cessation in Patients After Myocardial Infarction: The TELEGRAM-MI Randomized Controlled Trial","TELEGRAM-MI","Inclusion Criteria:\n\n* Willing and able to provide written informed consent.\n* Age 18 years or older.\n* Hospitalization with a confirmed diagnosis of acute myocardial infarction (MI), including both ST-elevation MI (STEMI) and non-ST-elevation MI (NSTEMI).\n* Current smoker at the time of index MI: self-reported smoking of at least one cigarette per day in the month prior to hospitalization.\n* Regular user of the Telegram messenger application (app installed on a personal smartphone).\n* Possession of a smartphone with internet access and a valid phone number.\n* Ability and willingness to provide contact information for a close relative or cohabiting person who can verify smoking status at follow-up.\n\nExclusion Criteria:\n\n* Smoking cessation more than 1 month prior to the index MI hospitalization.\n* Physical or cognitive impairment that prevents the use of a smartphone (e.g., severe visual\u002Fhearing impairment, inability to read or respond to messages).\n* Inability to read and understand the Russian language fluently.\n* Comorbid condition with a life expectancy of less than 1 year.\n* Active severe mental illness (e.g., psychosis, severe untreated depression) that would impede understanding of the protocol or adherence.\n* Unwillingness or inability to provide contact details for a close relative for outcome verification.",{"count":407,"type":21},142,[24],"This randomized controlled trial will evaluate whether a 6-month behavioral intervention delivered via Telegram messenger increases smoking cessation rates in patients after myocardial infarction (MI).\n\nAdult smokers hospitalized with acute MI who regularly use Telegram will be randomly assigned to either:\n\n* INTERVENTION GROUP: Standard care plus a 6-month Telegram chatbot program providing personalized motivational messages, cognitive-behavioral techniques for craving management, and relapse prevention support.\n* CONTROL GROUP: Standard care (routine physician advice to quit smoking) plus basic surveys via Telegram without therapeutic content.\n\nThe primary outcome is 30-day point prevalence abstinence at 6 months, verified by blinded telephone interview with participant and corroborating report from a close relative. Secondary outcomes include changes in cigarette consumption, nicotine dependence, motivation, and intervention engagement metrics.\n\nThis study addresses the critical gap in smoking cessation support after hospital discharge and could provide evidence for a scalable digital health solution in cardiac secondary prevention.",[411,226,27],"Myocardial Infarction (MI)",[413,414,415,416,417,418,419],"Telegram","Chatbot","Digital Health","Behavioral Intervention","Secondary Prevention","Randomized Controlled Trial","Cardiac Rehabilitation","2026-07-26",{"date":391,"type":35},{"date":423,"type":21},"2026-07-27",{"date":425,"type":21},"2027-08-01",{"name":427,"class":42},"ITMO University",{"id":429,"slug":430,"hasResults":12,"nctId":431,"briefTitle":432,"officialTitle":433,"acronym":4,"eligibilityCriteria":434,"healthyVolunteers":52,"sex":17,"minAge":53,"maxAge":4,"enrollmentInfo":435,"targetDuration":4,"studyType":22,"phases":437,"briefSummary":438,"conditions":439,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":440,"lastUpdatePostDateStruct":441,"startDateStruct":442,"completionDateStruct":444,"leadSponsor":446,"locationsCount":43},"100561036","rural-smoking-cessation-100561036","NCT06584929","Rural Smoking Cessation","Evaluating Population-Based Strategies for Rural Smoking Cessation","Inclusion Criteria:\n\n* ≥ 21 years\n* smoke ≥ 5 cigarettes per day\n* daily access to their own iPhone\u002FAndroid smartphone or tablet\n\nExclusion Criteria:\n\n* past 30-day NRT use or contraindications listed on the NRT labels\n* currently pregnant\u002Fbreastfeeding",{"count":436,"type":21},544,[24],"Understanding ways to help people who live in rural areas quit smoking is a public health priority. quitting smoking among rural people who smoke is a critical public health concern. People in rural areas smoke at higher rates than those in urban areas, experience high rates of smoking caused cancers and deaths. We are recruiting rural people from around the country to better understand how different quit smoking methods can improve a person's chances of successfully quitting smoking.",[27],"2026-07-24",{"date":423,"type":35},{"date":443,"type":35},"2026-03-17",{"date":445,"type":21},"2029-08-31",{"name":447,"class":42},"Masonic Cancer Center, University of Minnesota",{"id":449,"slug":450,"hasResults":12,"nctId":451,"briefTitle":452,"officialTitle":452,"acronym":4,"eligibilityCriteria":453,"healthyVolunteers":52,"sex":17,"minAge":18,"maxAge":454,"enrollmentInfo":455,"targetDuration":4,"studyType":22,"phases":457,"briefSummary":458,"conditions":459,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":460,"lastUpdatePostDateStruct":461,"startDateStruct":462,"completionDateStruct":464,"leadSponsor":466,"locationsCount":43},"100639319","adaptive-mobile-interventions-to-reduce-cancer-risk-behaviors-100639319","NCT07585357","Adaptive Mobile Interventions to Reduce Cancer Risk Behaviors","Inclusion Criteria:\n\n* live in the U.S.;\n* are between 18 and 40 years of age;\n* own a smartphone with iOS and Android operating system and GPS capabilities;\n* are carrying smartphone every day;\n* are willing to participate in the study for 44 days and give the research team access to the phone GPS data;\n* have smoked ≥100 cigarettes in the participant's life and currently smoke at least 3 cigarettes per day on 5 or more days of the week;\n* are planning to quit smoking within the next 30 days.\n\nExclusion Criteria:\n\n* None","40 Years",{"count":456,"type":21},7,[24],"Tobacco use remains the leading cause of preventable death, causing over 400,000 annual deaths in the United States alone. Smartphone-based interventions, particularly those leveraging real-time adaptive messaging, represent a promising yet underutilized approach to delivering personalized tobacco and cannabis treatment. The investigator's ongoing NCI funded micro-randomized trial (MRT; R01 CA246590) has shown initial feasibility in reducing smoking urges through situationally tailored cognitive-behavioral therapy (CBT) and mindfulness-based acceptance and commitment-based therapy (ACT) messages triggered by real-time contextual data (e.g., geolocation, momentary stress). To advance from a static MRT framework to a dynamic, data-driven just-in-time adaptive intervention (JITAI), this project aims to develop, test, and refine a reinforcement learning (RL) algorithm that can continuously adapt to user needs in real-time, enhancing treatment outcomes for various tobacco and cannabis products.\n\nTo ensure optimal usability and engagement, the investigators will conduct user-centered testing with the developed RL-based intervention delivery in one cohort (N=7) over 45 days. This will include usability assessment via the System Usability Scale, analysis of app interaction metrics, and semi-structured interviews to gather feedback for refining message content, timing, and design.",[27],"2026-07-23",{"date":423,"type":35},{"date":463,"type":35},"2026-07-06",{"date":465,"type":21},"2026-09",{"name":467,"class":42},"Johns Hopkins Bloomberg School of Public Health",{"id":469,"slug":470,"hasResults":12,"nctId":471,"briefTitle":472,"officialTitle":473,"acronym":4,"eligibilityCriteria":474,"healthyVolunteers":52,"sex":17,"minAge":53,"maxAge":4,"enrollmentInfo":475,"targetDuration":4,"studyType":22,"phases":477,"briefSummary":479,"conditions":480,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":481,"lastUpdatePostDateStruct":482,"startDateStruct":483,"completionDateStruct":484,"leadSponsor":486,"locationsCount":488},"100625191","phase-4-my-path-to-quit-tobacco-100625191","NCT07419425","My Path to Quit Tobacco","Comparing Three Multicomponent Interventions to Help Adults Quit Smoking","Inclusion Criteria:\n\n* self-identify as Black\n* smoke cigarettes (greater than or equal to 1 cigarette on greater than or equal to 4 days\u002Fweek)\n* motivated to quit smoking\n* willing to discontinue any non-study smoking cessation pharmacotherapy use during study treatment.\n\nExclusion Criteria:\n\n* currently taking bupropion for non-smoking cessation reasons",{"count":476,"type":21},1550,[478],"PHASE4","The overarching goal of this program of research is to reduce smoking-related health disparities by increasing smoking cessation among Black adults. The goal of this research proposal is to determine whether more intensive, culturally specific, evidence-based interventions are more effective at promoting long-term cessation and other key patient-centered outcomes compared to the usual evidence-based standard of care: services provided by a state-run quitline. This study compares the relative effectiveness of three different treatments (Standard, Intensive, and Intensive Incentivized) on long-term smoking cessation (biochemically confirmed abstinence from combusted tobacco at 26-weeks post-target quit day) among Black adults who smoke and want to quit.",[27],"2026-07-22",{"date":460,"type":35},{"date":463,"type":35},{"date":485,"type":21},"2030-01",{"name":487,"class":42},"University of Wisconsin, Madison",5,{"id":490,"slug":491,"hasResults":12,"nctId":492,"briefTitle":493,"officialTitle":493,"acronym":494,"eligibilityCriteria":495,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":496,"enrollmentInfo":497,"targetDuration":4,"studyType":22,"phases":499,"briefSummary":500,"conditions":501,"keywords":502,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":481,"lastUpdatePostDateStruct":506,"startDateStruct":507,"completionDateStruct":509,"leadSponsor":510,"locationsCount":397},"100605715","precision-treatment-to-promote-smoking-cessation-and-survival-in-oncology-patients-100605715","NCT07166120","Precision Treatment to Promote Smoking Cessation and Survival in Oncology Patients","PROMISE","Eligibility Criteria for Clinicians:\n\n* Clinician from participating oncology\u002Fhematology clinic\n* At least 18 years of age\n* Can speak and understand English\n\nInclusion Criteria for Patients:\n\n* Patient at participating clinic\n* Age 18-89 years\n* Current smoking (average cigarettes per day ≥5)\n* Can speak and understand English\n* Willing to consider medication to help reduce craving or smoking such as nicotine patch, lozenge, or varenicline\n\nExclusion Criteria for Patients:\n\n* Active use of smoking cessation medication (within the past 30 days)\n* Receipt of smoking cessation medication or prescription for smoking cessation medication (within the past 30 days)\n* Having a contradiction for cNRT or varenicline (allergic reactions, current cardiac problems, pregnancy)\n* Patients who were deemed by the investigator to be ineligible for participation in the trial","89 Years",{"count":498,"type":21},132,[24],"This study evaluates the feasibility and preliminary effects of precision tobacco treatment, compared to usual care, on promoting tobacco treatment in oncology patients and providers in the oncology care setting. The precision treatment intervention includes personalized tobacco treatment recommendations using the patient's clinical, genetic, and biomarker information. This intervention may increase patient receipt of tobacco treatment, patient medication use, and patient smoking abstinence at 6 months.",[27,62,360],[503,504,505],"Genetics","Primary Care Physicians","Tobacco Treatment",{"date":440,"type":35},{"date":508,"type":35},"2025-09-11",{"date":210,"type":21},{"name":372,"class":42},{"id":512,"slug":513,"hasResults":12,"nctId":514,"briefTitle":515,"officialTitle":516,"acronym":517,"eligibilityCriteria":518,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":519,"targetDuration":4,"studyType":22,"phases":521,"briefSummary":522,"conditions":523,"keywords":525,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":481,"lastUpdatePostDateStruct":530,"startDateStruct":531,"completionDateStruct":533,"leadSponsor":535,"locationsCount":213},"100566169","smoking-cessation-intervention-including-health-navigators-to-address-unmet-social-needs-of-parents-who-smoke-100566169","NCT06651684","Smoking Cessation Intervention Including Health Navigators to Address Unmet Social Needs of Parents Who Smoke","A Randomized Controlled Trial of a Smoking Cessation Intervention Including Health Navigators to Address Unmet Social Needs of Parents Who Smoke","CanCEASE-2","Inclusion Criteria:\n\n* Parents or legal guardians aged ≥18 years, with child(ren) aged 0-17 years, attending a regular scheduled medical appointment in one of the study sites.\n* Pregnant patients aged ≥18 years who are parents or legal guardians of child(ren) aged 0-17 years coming in for an prenatal appointment.\n* Smokers with at least one self-reported social risk as assessed by validated screening questions on the domains employment, housing stability, ability to pay for utilities, financial resource strain, food security, transportation, childcare, parent education and health literacy.\n* Sufficiently proficient in French or English to understand and complete study questionnaires.\n\nExclusion Criteria:\n\n* Families presenting at the clinic for an urgent medical issue.\n* Parents without at least one social risk.\n* If both parents smoke, only one parent will be eligible to participate.",{"count":520,"type":21},1000,[24],"Background: The goal of this study is to address parental smoking and social adversity, which can present an obstacle for smoking cessation, in order to decrease childhood exposure to second-hand cigarette smoke. To address these factors, this study includes a smoking cessation intervention for parents and legal guardians recruited in pediatric clinics (CanCEASE), as well as the support of a Health Navigator (HN) to work with the participant towards the resolution or mitigation of unmet social needs.\n\nParticipants: The research team will recruit one thousand participants from pediatric outpatient clinics within two healthcare centres in and around the city of Montreal, Canada, over the course of 2.5 years. Eligible persons are parents and legal guardians, of any sex and gender, accompanying children under 18 to their scheduled medical appointments, and who report at least one social risk in selected areas (i.e., employment, housing stability, ability to pay for utilities, financial resource strain, food security, transportation, childcare, parent education and health literacy). Participants must also be 18 years old or older with sufficient proficiency in French or English to complete the interviews and questionnaires. In households in which both parents smoke, only one will be eligible to participate, but smoking cessation information will be offered to both. Families presenting at the clinic for an urgent medical issue are not eligible to participate.\n\nIntervention: Participants will be divided into control group (care as usual with CanCEASE at the end of the study period) and intervention (CanCEASE + Health navigator). All participants will complete questionnaires at Baseline, 6 and 12 months. The intervention group will receive CanCEASE at the end of each questionnaire. Controls will receive CanCEASE at 12 months. The intervention group will have the possibility to meet with the HNs and will be invited to commit to at least two sessions (i.e.: evaluation and a follow up), with the option to book more time as needed.\n\nAims and hypotheses: Examining how effective the combination of CanCEASE with HN support is in helping parents with unmet social needs quit smoking. Investigators will also examine the effects of the intervention on status of unmet social needs, if the intervention was implemented as planned and well accepted by clinics and participants, and what is the cost of the intervention for each person who quits smoking.",[27,524],"Tobacco Dependence",[140,526,527,528,529],"Social risk","Second hand smoke","Health navigator","Unmet social needs",{"date":440,"type":35},{"date":532,"type":35},"2026-03-26",{"date":534,"type":21},"2030-02",{"name":536,"class":42},"St. Justine's Hospital",{"id":538,"slug":539,"hasResults":12,"nctId":540,"briefTitle":541,"officialTitle":542,"acronym":543,"eligibilityCriteria":544,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":545,"targetDuration":4,"studyType":22,"phases":547,"briefSummary":548,"conditions":549,"keywords":4,"overallStatus":232,"whyStopped":4,"lastUpdateSubmitDate":481,"lastUpdatePostDateStruct":551,"startDateStruct":552,"completionDateStruct":553,"leadSponsor":554,"locationsCount":43},"100550088","pain-and-smoking-study-2-100550088","NCT06442514","Pain and Smoking Study 2","Enhancing an Intervention for Smokers With Chronic Pain Using IVR: A Randomized Clinical Trial of Smoking Cessation Counseling for Veterans","PASS2","Inclusion Criteria:\n\n* being an enrolled Veteran at VACHS\n* current tobacco use\n* willingness to make a quit attempt\n* significant chronic pain defined as \\>\u002F=4 on the pain intensity portion of the Brief Pain Inventory (BPI) for more than 90 days\n\nExclusion Criteria:\n\n* active diagnosis of dementia or psychosis in medical record\n* severely impaired hearing or speech\n* lack of telephone access\n* enrollment in concurrent research study that might affect main outcomes of this study\n* terminal illness\n* non-English speaking\n* pregnancy\n* provider advising against exercise\n* planned surgeries\n* clinically significant depressive symptoms (\\>10 PHQ-9)",{"count":546,"type":21},220,[24],"PASS2 aims to expand upon the recently completed study (PASS intervention), which tested the telephone delivery of a cognitive behavioral intervention (CBI). This study will use nightly surveys to optimize the intervention's effectiveness for smoking cessation among Veteran smokers with chronic pain.",[62,550,27],"Pain",{"date":440,"type":35},{"date":340,"type":21},{"date":345,"type":21},{"name":555,"class":556},"VA Office of Research and Development","FED",{"id":558,"slug":559,"hasResults":12,"nctId":560,"briefTitle":561,"officialTitle":562,"acronym":4,"eligibilityCriteria":563,"healthyVolunteers":12,"sex":17,"minAge":53,"maxAge":133,"enrollmentInfo":564,"targetDuration":4,"studyType":22,"phases":566,"briefSummary":567,"conditions":568,"keywords":570,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":575,"lastUpdatePostDateStruct":576,"startDateStruct":578,"completionDateStruct":580,"leadSponsor":582,"locationsCount":584},"100641102","phase-2-multi-site-trial-of-tirzepatide-for-smoking-cessation-100641102","NCT07602699","Multi-Site Trial of Tirzepatide for Smoking Cessation","A Multi-Site Trial of Tirzepatide for Smoking Cessation","Inclusion Criteria:\n\n1. Age 21-65 years\n2. Body mass index ≥ 25kg\u002Fm2 at the baseline screening\n3. Reporting ≥10 cigarettes per day, on average, for the past 6 months and \\> 2 year duration of smoking\n4. Interest in making a long-term cessation attempt within the next 30-60 days\n5. Willingness to receive study medication and standard-of-care smoking cessation supports (nicotine replacement therapy and a smoking cessation app)\n6. Ability to adhere to weekly visits and study procedures over the study period (i.e., no plans to move or travel for extended periods)\n7. Exhaled CO of \\>5ppm at baseline\n8. Use of an acceptable birth control method for female participants\\*\n9. Ability to read and communicate in English\n\nExclusion Criteria:\n\n1. BMI \\\u003C 25 kg\u002Fm2 at screening\n2. History of diabetes, diabetes-attributable medical conditions, or HbA1c ≥6.5% at baseline\n3. Recent (past 90 days) active suicidal ideation or lifetime history of suicide attempt\n4. Current treatment for psychotic disorders or mood disorders with psychotic features (e.g., schizophrenia, schizoaffective disorder, depression with psychotic features), current treatment for bipolar disorder (with or without psychotic features), or current secondary psychosis due to substance use or another medical condition\n5. Meeting DSM-5 criteria for a current (past 12 months) substance use disorder other than tobacco use disorder, mild or moderate cannabis use disorder, or mild or moderate alcohol use disorder.\n6. Recent (past 30 day) self-report of illicit drug use (excluding cannabis) or non-prescribed opioids; or positive urine screen for illicit drugs. A positive screen for opioids will be allowed if the participant is prescribed an opioid replacement therapy medication and can provide documentation.\n7. Past 30-day initiation of psychiatric medications (e.g., SSRIs) or changes to medication dose\n8. Treatment with tirzepatide or another GLP-1RA medication in the prior 6 months\n9. Current (past month) treatment with other weight loss, diabetes, or smoking cessation medications (varenicline or bupropion; excluding nicotine replacement products)\n10. Severe GI disease (e.g., gastroparesis, ulcerative colitis).\n11. History of gastric bypass surgery or other surgeries of the stomach\n12. Any health condition or treatment\u002Fmedication that would preclude the use of tirzepatide or NRT, in the opinion of the study physician, including severe cardiovascular disease\n13. History of chronic pancreatitis or acute pancreatitis in the last 6 months\n14. Currently nursing, pregnant, or anticipating pregnancy\n15. History of diabetic retinopathy, proliferative retinopathy, or maculopathy\n16. Elevated serum lipase, amylase, bilirubin, or ALP, ALT, or AST (\\>5x upper limit of normal range)\n17. History of malignant neoplasms in the last 5 years, except non-melanoma skin cancer\n18. Inability to attend weekly clinic visits as scheduled (i.e., based on travel or work schedule)\n19. Currently enrolled in another clinical study involving an investigational product\n20. Currently living in the same household as someone taking a GLP-1 medication, or living with a current or former participant in the present trial\n21. Planned surgical procedures requiring anesthesia during the planned study medication period\n22. Personal or family history of medullary thyroid cancer\n23. Personal or family history of multiple endocrine neoplasia syndrome type 2 (MEN 2)\n24. Treatment with other weight loss (e.g., phentermine), or FDA-approved, non-NRT smoking cessation therapies (varenicline, bupropion) or FDA-approved AUD medications (naltrexone, acamprosate, disulfiram) or off-label AUD medications (e.g., topiramate) in the past 90 days\n25. Any health condition or treatment\u002Fmedication that would preclude use of tirzepatide or NRT, in the opinion of the site physicians including thyroid enlargement.",{"count":565,"type":21},300,[81],"This multi-site clinical trial will generate data on the efficacy of tirzepatide for smoking cessation and associated outcomes (e.g., post-cessation weight gain) in treatment-seeking people who smoke (PWS) with overweight or obesity. A sample of 300 treatment-seeking people who smoke with body mass index of 25 kg\u002Fm2 or greater will be recruited from four geographic sites (University of Southern California, Yale University, University of Chicago, and University of Colorado Anschutz Medical Campus) to participate in a parallel-arm, dose-escalating, placebo-controlled trial. Participants will attend weekly clinic visits to receive subcutaneous tirzepatide or placebo over 16 weeks (Visit Weeks 1-16), followed by follow-up visits at Week 17 and Week 27. Medication will be prescribed according to the standard dose titration schedule for the first 16 weeks of treatment (initial dose: 2.5mg\u002Fweek; final dose: 10mg\u002Fweek). All participants will also receive nicotine patches.",[27,569],"Smoking Behaviors",[571,572,573,574],"Addiction","GLP-1","Tirzepatide","Substance Use Disorder","2026-07-15",{"date":577,"type":35},"2026-07-17",{"date":579,"type":35},"2026-06-05",{"date":581,"type":21},"2028-09",{"name":583,"class":42},"University of Southern California",4,{"id":586,"slug":587,"hasResults":12,"nctId":588,"briefTitle":589,"officialTitle":590,"acronym":591,"eligibilityCriteria":592,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":133,"enrollmentInfo":593,"targetDuration":4,"studyType":22,"phases":595,"briefSummary":596,"conditions":597,"keywords":601,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":607,"lastUpdatePostDateStruct":608,"startDateStruct":610,"completionDateStruct":611,"leadSponsor":612,"locationsCount":43},"100604157","phase-4-varenicline-and-accelerated-transcranial-magnetic-stimulation-tms-for-quitting-nicotine-use-pilot-study-100604157","NCT07145866","Varenicline and Accelerated Transcranial Magnetic Stimulation (TMS) for Quitting Nicotine Use (Pilot Study)","Evaluation of Varenicline and Accelerated TMS for Reduction of Nicotine Use","V-TMS","Inclusion Criteria:\n\n* Age ≥ 18 and ≤65;\n* The ability to give written, informed consent;\n* Fluency in English;\n* Reported interest in quitting nicotine vaping or smoking within the next month;\n* Nicotine dependence, as defined by a score of ≥4 on the 10-question E-cigarette Dependence Inventory (ECDI) or Fagerström Test for Nicotine Dependence (FTND);\n* Smoke or vape nicotine daily for at least the past 90 days, as confirmed by self-report and timeline follow-back methods;\n* Saliva cotinine \\>30ng\u002FmL;\n\nExclusion Criteria:\n\n* Pregnancy or breastfeeding;\n* Use of smoking cessation pharmacotherapy in the past month;\n* Unwilling to abstain during the study from using smoking cessation aids other than those provided by the study;\n* Prior adverse drug reaction to varenicline;\n* Contraindication to D-Cycloserine (including allergy to D-Cycloserine, significant renal impairment or known kidney disease, pregnancy)\n* Receiving or planning to receive other TMS treatments or investigational drugs during course of participation\n* Contraindications to TMS (including seizures, metallic implants, severe existing tinnitus, etc.);\n* Contraindications to MRI (including presence of a cardiac pacemaker or pacemaker wires, metallic particles in the body, vascular clips in the head or previous neurosurgery, prosthetic heart valves, claustrophobia);\n* Inpatient psychiatric hospitalization or suicide attempts in the past six months, or recent active suicidal ideation or suicidal behavior identified at enrollment or baseline visits;\n* History of seizures and\u002For history of TBI subtypes associated with elevated seizure risk (e.g. penetrating injury and intraparenchymal hemorrhage)\n* History of unstable neurological illness or major medical illness, such as epilepsy or renal impairment, in the past six months, unless clearly resolved;\n* In the opinion of the investigators, evidence of active problem substance use severe enough to compromise ability to safely participate;\n* In the opinion of the investigators, unable to safely participate in this study and\u002For provide reliable data (e.g., claustrophobia, unable to tolerate TMS or MRI procedures, etc.).",{"count":594,"type":21},30,[478],"The goal of this clinical trial is to learn if a combination of varenicline and enhanced accelerated Transcranial Magnetic Stimulation (aTMS) works to help adults quit using nicotine products. Researchers will compare varenicline + active aTMS with a single dose of D-Clycloserine to varenicline + sham (inactive) aTMS with a placebo pill to see the effect of enhanced aTMS on reaching abstinence. The main question it aims to answer is: Does receiving active enhanced aTMS + varenicline lead to higher abstinence rates and lower nicotine craving?\n\nParticipants will be asked to:\n\n* Complete 2 brain MRI scans\n* Take varenicline every day for 12 weeks\n* Quit using nicotine products at the end of the second week of varenicline\n* Complete one day of up to 20 TMS treatments\n* Take a single dose of D-Cycloserine medication on the day of TMS treatment\n* Complete 12 brief, weekly follow-up visits\n* Complete a brief daily survey each day that they take the study drug",[60,598,599,27,600],"Transcranial Magnetic Stimulation","Vaping","Smoking (Tobacco) Addiction",[599,62,602,603,604,115,598,605,606],"Nicotine","Adults","Cessation","TMS","D-Cycloserine","2026-07-09",{"date":609,"type":35},"2026-07-13",{"date":157,"type":21},{"date":159,"type":21},{"name":613,"class":42},"Massachusetts General Hospital",{"id":615,"slug":616,"hasResults":12,"nctId":617,"briefTitle":618,"officialTitle":618,"acronym":4,"eligibilityCriteria":619,"healthyVolunteers":12,"sex":620,"minAge":18,"maxAge":621,"enrollmentInfo":622,"targetDuration":4,"studyType":22,"phases":624,"briefSummary":625,"conditions":626,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":607,"lastUpdatePostDateStruct":628,"startDateStruct":629,"completionDateStruct":631,"leadSponsor":633,"locationsCount":43},"100422671","phase-4-modifying-progesterone-and-estradiol-levels-to-prevent-postpartum-cigarette-smoking-relapse-and-reduce-secondhand-smoke-exposure-in-infants-and-children-100422671","NCT04783857","Modifying Progesterone and Estradiol Levels to Prevent Postpartum Cigarette Smoking Relapse and Reduce Secondhand Smoke Exposure in Infants and Children","Inclusion Criteria:\n\n* Ability to provide informed consent,\n* Aged 18 to 45 years old\n* Self-reported stable physical and mental health\n\n  1. self-report uncomplicated pregnancy at gestational week 30 or beyond, or\n  2. self-report the birth of a child within the past 6 months\n* History of ≥ 4 cigarettes per month during the six months prior to pregnancy\n* At enrollment, self-report of motivation to become and\u002For remain abstinent after delivery ≥ 6 on a 10 point Likert-type scale\n* Willingness to protect against pregnancy following day 0 to week 12 of the study\n* Participants must live in the continental US and have a device to fully participate in the protocol\n\nExclusion Criteria:\n\n* Current daily use of nicotine replacement therapy or smoking cessation medications, with the exception of e-cigarettes\n* Current major depressive disorder based on the Patient Health Questionnaire-9 (PHQ-9) and the Beck Depression Inventory\n* Contraindication to progesterone treatment (e.g., current use of drugs that may inhibit CYP3A4; current or history of deep vein thrombosis, pulmonary embolus, clotting or bleeding disorder, hypertension, stroke, heart disease, or liver dysfunction or disease; or peanut allergy),\n* Current or within the past 3 months treatment for illicit drug use or alcohol use\n* Any condition or issue that, in the opinion of the clinical team, precludes participation in the trial.","FEMALE","45 Years",{"count":623,"type":21},171,[478],"The investigators aim to address the following specific aims:\n\n* Determine the efficacy of Prog in preventing postpartum smoking relapse and reducing smoking relapse risk factors.\n* Examine the effects of this maternal smoking intervention on infant health.\n* Examine racial and ethnic differences in intervention outcomes.",[62,27,627],"Smoking Reduction",{"date":609,"type":35},{"date":630,"type":35},"2022-04-14",{"date":632,"type":21},"2027-06-02",{"name":634,"class":42},"University of Minnesota"]